- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
EyeCon 2022: Emerging therapies in geographic atrophy
Rishi Singh, MD, of Cleveland Clinic Florida, touches upon the various advancements that are making a difference for clinicians and patients and reducing their progression in this disease state.
This transcript has been edited for clarity:
Hi, my name is Rishi Singh from Cleveland Clinic Florida. It's my pleasure to be here at this year's EyeCon 2022 meeting in Marco Island, Florida, with all of my friends and colleagues.
Today, I'm going to be speaking about emerging therapies in geographic atrophy. For many years, we have had great treatments for wet macular degeneration. Unfortunately, we have had to ignore the dry disease because we just didn't have therapies available.
We're learning more about the imaging techniques, the biomarkers that assure us progression in this disease state, as well as learning about the emerging therapeutics and the alternative complement pathway as well as gene therapy that are making a difference for our patients and reducing their progression of this disease state.
I'm really excited to learn more from my colleagues and friends who are also presenting on various other retinal topics, and we're going to learn a lot from this program today.
